stocks logo

RNA

Avidity Biosciences Inc
$
36.270
+3.06(9.214%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
37.590
Open
33.500
VWAP
35.91
Vol
6.08M
Mkt Cap
4.37B
Low
32.720
Amount
218.36M
EV/EBITDA(TTM)
--
Total Shares
107.77M
EV
2.99B
EV/OCF(TTM)
--
P/S(TTM)
495.84
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.60M
-46.07%
-1.104
+37.96%
1.60M
-31.4%
-1.024
+57.55%
1.61M
-21.5%
-0.956
+47.05%
Estimates Revision
The market is revising Downward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by -12.9% over the past three months. During the same period, the stock price has changed by 16.23%.
Revenue Estimates for FY2025
Revise Downward
down Image
-12.9%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.21%
In Past 3 Month
Stock Price
Go Up
up Image
+16.23%
In Past 3 Month
16 Analyst Rating
up Image
84.89% Upside
Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 67.06 USD with a low forecast of 50.00 USD and a high forecast of 96.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
0 Hold
0 Sell
Strong Buy
up Image
84.89% Upside
Current: 36.270
sliders
Low
50.00
Averages
67.06
High
96.00
Evercore ISI
Gavin Clark-Gartner
Outperform
maintain
$60 -> $70
2025-07-11
Reason
Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on Avidity Biosciences to $70 from $60 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Goldman Sachs
NULL
to
Buy
initiated
$55
2025-07-10
Reason
Goldman Sachs resumed coverage of Avidity Biosciences with a Buy rating and $55 price target. The firm expects clarity over the next 12-18 months on the company's regulatory outlook.
Bernstein
Outperform
initiated
$50
2025-06-24
Reason
Wolfe Research
Andy Chen
Outperform
initiated
$55
2025-06-18
Reason
Wolfe Research
NULL -> Outperform
initiated
$55
2025-06-17
Reason
Wolfe Research initiated coverage of Avidity Biosciences with an Outperform rating and $55 price target.
Barclays
Overweight
maintain
$57 -> $59
2025-06-10
Reason

Valuation Metrics

The current forward P/E ratio for Avidity Biosciences Inc (RNA.O) is -7.90, compared to its 5-year average forward P/E of -7.87. For a more detailed relative valuation and DCF analysis to assess Avidity Biosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.87
Current PE
-7.90
Overvalued PE
-3.46
Undervalued PE
-12.29

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.67
Current EV/EBITDA
-4.96
Overvalued EV/EBITDA
-1.07
Undervalued EV/EBITDA
-8.27

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
212.68
Current PS
628.80
Overvalued PS
393.71
Undervalued PS
31.66

Financials

Annual
Quarterly
FY2025Q1
YoY :
-55.60%
1.57M
Total Revenue
FY2025Q1
YoY :
+70.39%
-131.52M
Operating Profit
FY2025Q1
YoY :
+68.14%
-115.77M
Net Income after Tax
FY2025Q1
YoY :
+13.92%
-0.90
EPS - Diluted
FY2025Q1
YoY :
+80.35%
-128.58M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+209.26%
-4.09K
FCF Margin - %
FY2025Q1
YoY :
+278.72%
-7.36K
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 360.31% over the last month.
Sold
0-3
Months
1.1M
USD
4
3-6
Months
3.3M
USD
9
6-9
Months
11.0M
USD
17
0-12
Months
15.4M
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
650.0K
Volume
1
6-9
Months
456.5K
Volume
4
0-12
Months
524.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
4
1.8M
Volume
Months
6-9
2
2.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RNA News & Events

Events Timeline

2025-07-23 (ET)
2025-07-23
09:06:43
Avidity Biosciences receives FDA BTD for delpacibart zotadirsen
select
2025-07-17 (ET)
2025-07-17
11:58:09
Avidity, Phathom mentioned as potential takeout targets at Needham
select
2025-06-09 (ET)
2025-06-09
15:18:19
Avidity data strengthens accelerated approval case, says H.C. Wainwright
select
Sign Up For More Events

News

9.0
15:03 PMYahoo Finance
PinnedAvidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation
9.0
07-23NASDAQ.COM
Avidity Biosciences On Track To Seek Approval For Del-zota In DMD By Year-End
9.0
07-23PRnewswire
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Sign Up For More News

FAQ

arrow icon

What is Avidity Biosciences Inc (RNA) stock price today?

The current price of RNA is 36.27 USD — it has increased 9.21 % in the last trading day.

arrow icon

What is Avidity Biosciences Inc (RNA)'s business?

arrow icon

What is the price predicton of RNA Stock?

arrow icon

What is Avidity Biosciences Inc (RNA)'s revenue for the last quarter?

arrow icon

What is Avidity Biosciences Inc (RNA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Avidity Biosciences Inc (RNA)'s fundamentals?

arrow icon

How many employees does Avidity Biosciences Inc (RNA). have?

arrow icon

What is Avidity Biosciences Inc (RNA) market cap?